Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

 Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

Takeda, Neurocrine, Collaborate, Seven, Neuro Programs, Worth Up to, $2B

Shots:

  • Takeda to receive $120M as upfront in cash, ~ $495M as development milestones, and ~$1.4B as commercial milestones along with royalties on net sales of the therapies. Takeda retains the ability to opt-in or out of a 50:50 profit share on all clinical programs at certain development events
  • For any asset in which Takeda shares equal profit, Takeda will not receive development or commercial milestones. Neurocrine get an exclusive license for seven pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia
  • The collaboration involves three clinical program includes TAK-831, TAK-653, TAK-041 and the rights to four preclinical programs

Click here to read full press release/ article | Ref: Takeda | Image: Future Medicine India

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post